InvestorsHub Logo

HDGabor

04/05/20 6:05 PM

#262595 RE: JDUR #262582

J-

-Where are the generics at in determining bio-equivalence to Vascepa with the FDA?

ANDAs were submitted in 2016, waiting for approval. Could come tomorrow …

-Can a settlement with generics be reached per settlement terms with Teva?

No way … wishful thinking

-Will AMRN give us some more info or throw us a bone with unaudited Q1 results?

Not likely … and no reason of it

-If the generic launches, will Europe honor Teva's exclusivity rights, thus voiding the 10 year exclusivity?

More =/ most likely TEVA settlement is about the US … nothing to do with Europe.

Best,
G